| Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women. | |
| | |
MedLine Citation:
|
PMID: 16864147 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Blood pressure, which generally increases after menopause, is one of the best tools to characterize cardiovascular disease. The renin-aldosterone system plays a role in determining cardiovascular risk and the role of estrogen in the regulation of angiotensinogen gene expression and serum levels is well known. Raloxifene can induce endothelium-dependent vasodilation without affecting endothelium-independent vasorelaxation. The aim of the study was to investigate the effects of raloxifene on the renin-aldosterone system and blood pressure in postmenopausal women. DESIGNS: Forty women, 54-59 years of age, in physiological menopause for 6 months to 4 years, were enrolled in the study and treated with raloxifene 60 mg/day for 6 months. All had blood pressure less than 130/85 mm Hg at the start of the study. The women were divided into two groups: the first (group A; 20 women) with normal blood pressure and the second (group B; 20 women) with previous high blood pressure treated with antihypertensive drugs, not angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. RESULTS: No significant changes in plasma renin activity (PRA) or plasma concentrations of aldosterone were observed between the two groups after 6 months of raloxifene use. There was a slight reduction in PRA (11+/-4% for group A and 13+/-5% for group B) and in plasma levels of aldosterone (3.6+/-0.5% and 4.6+/-0.5%, respectively) with respect to basal values, but neither change was statistically significant. CONCLUSIONS: The results of the present study show that raloxifene at 60 mg/day dose is well tolerated and has no clinical impact on blood pressure, PRA or aldosterone in postmenopausal women. |
| | |
Authors:
|
Giuseppe Morgante; Ada Delia; Maria C Musacchio; F M Severi; Felice Petraglia; Vincenzo De Leo |
Related Documents
:
|
7922187 - Hypertension and adrenal disorders. 1269097 - Relation between plasma renin activity, angiotensin, and aldosterone and blood pressure... 1781767 - Myocardial fibrosis: role of ventricular systolic pressure, arterial hypertension, and ... 3050197 - Periodic fluctuation of blood pressure and its management in a patient with pheochromoc... 15923817 - Side effects of ambulatory blood pressure monitoring. 2061837 - Influence of pressure alterations on tone and vasomotion of isolated mesenteric small a... |
Publication Detail:
|
Type: Controlled Clinical Trial; Journal Article |
Journal Detail:
|
Title: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology Volume: 22 ISSN: 0951-3590 ISO Abbreviation: Gynecol. Endocrinol. Publication Date: 2006 Jul |
Date Detail:
|
Created Date: 2006-07-25 Completed Date: 2007-01-19 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8807913 Medline TA: Gynecol Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 376-80 Citation Subset: IM |
Affiliation:
|
Department of Pediatrics, Obstetrics and Reproductive Medicine, Section of Obstetrics and Gynecology, University of Siena, Siena, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aldosterone
/
blood* Antihypertensive Agents / pharmacology Blood Pressure / drug effects* Bone Density / drug effects Female Humans Middle Aged Osteoporosis, Postmenopausal / drug therapy Postmenopause Raloxifene / pharmacology*, therapeutic use Renin / blood* Selective Estrogen Receptor Modulators / pharmacology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 0/Selective Estrogen Receptor Modulators; 52-39-1/Aldosterone; 84449-90-1/Raloxifene; EC 3.4.23.15/Renin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone ...
Next Document: Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdom...